Business
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize Canada NewsWire Issued on b...
About this update from Prime Drink Group Corp
[{"type":"text","content":"\n\n\nGene Therapy: 5 Biotech Stocks Chasing the $36B Prize\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nIssued on behalf of Avant Technologies Inc.\nVANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source[1]. The FDA approved three transformative cell therapies this December alone, marking an inflection point where living medicine moves from experimental concept to commercial reality[2]. This revolution in restorative biology defines the pipelines of Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), CRISPR Therapeutics (NASDAQ: CRSP), Prime Medicine, Inc. (NASDAQ: PRME), and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).\n\n\n\n\n\n\n\nThe cell and gene therapy sector is projected to reach $39.61 billion by 2034, growing at a 17.98% compound annual rate as precision-based therapies address previously untreatable genetic disorders[3]. Manufacturing breakthroughs in viral vector delivery are now enabling scalable production of these therapies, driving capital inflows from investors betting on functional cures rather than lifelong symptom management[4].\nAvant Technologies, Inc. (OTCQB: AVAI) is developing cell-based therapies for diabetes, aging, and chronic diseases using a proprietary encapsulation technology that protects genetically modified therapeutic cells from immune rejection. The company operates through two strategic joint ventures focused on addressing massive global health markets.\nThe first, Insulinova, Inc., is a partnership with SGAustria Pte. Ltd., through which Avant is developing treatments for type 1 and insulin-dependent type 2 diabetes. The approach centers on a cell encapsulation technology that allows genetically modified insulin-producing cells to survive long-term in the body without being susceptible to any immune system attacks. This solves a fundamental problem that historically required patients ...